GlassScriptPhysician profile
Ermil Wagner
NPI 1922193028
$3,463.00
in general payments reported to CMS, 2019-2025
26 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $443 · 2021: $1,037 · 2022: $481 · 2023: $354 · 2024: $445 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $735.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Harmony Biosciences LLC | $530.57 | 2021-2025 | Wakix |
| Lilly USA, LLC | $386.67 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $325.83 | 2020-2024 | |
| Jazz Pharmaceuticals INC. | $197.10 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.81 | 2019-2024 | Jardiance, Tradjenta |
| Vanda Pharmaceuticals INC. | $166.49 | 2019-2021 | |
| Eisai INC. | $110.36 | 2020-2021 | |
| Inspire Medical Systems, INC. | $107.43 | 2024-2025 | Inspire |
| Ultragenyx Pharmaceutical INC. | $79.14 | 2021-2023 | |
| Amgen INC. | $78.21 | 2019 | |
| Glaxosmithkline, LLC. | $75.83 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $69.58 | 2021 | |
| Abbott Laboratories | $68.63 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $63.50 | 2023-2024 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.83 | 2020 | |
| Stryker Corporation | $34.69 | 2022 | |
| Merck Sharp & Dohme LLC | $29.37 | 2019-2021 | |
| Philips North America LLC | $27.39 | 2021-2025 | Amara View |
| Idorsia Pharmaceuticals US INC | $24.05 | 2025 | Quviviq |
| Ibsa Pharma INC. | $22.41 | 2020 | |
| Gilead Sciences, INC. | $21.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $20.53 | 2020 | |
| Hologic Sales and Service, LLC | $17.15 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.72 | 2019 | |
| Lucid Diagnostics INC. | $12.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ermil Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.